Proof Of Concept Use of MTH1 Inhibitors as New Treatments for cancer
"In our ERC grant GEnetic NEtworks as a tool for anti-CAncer Drug Development we used phenotypic screening and genetic networks to identify the DNA repair protein MTH1 as a critical component for cancer cell survival and we develo...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
GENECADD
GEnetic NEtworks as a tool for anti CAncer Drug Development
3M€
Cerrado
TEDCIP
Targeting epigenetic demethylases development of covalent i...
183K€
Cerrado
CODIC
COmmercializing first in class dCTPase Inhibitors for treatm...
150K€
Cerrado
SAF2015-74072-JIN
DRIVERMAP: ESTIMANDO LA RELEVANCIA DE LAS MUTACIONES ONCOGEN...
205K€
Cerrado
Oncoswitch
Switchable in vivo genetic models to identify cancer drug ta...
2M€
Cerrado
SAF2013-49056-R
ANALISIS GENOMICO-FUNCIONAL DE LA RESISTENCIA A LAS TERAPIAS...
133K€
Cerrado
Información proyecto POCUMINT
Líder del proyecto
KAROLINSKA INSTITUTET
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
165K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
"In our ERC grant GEnetic NEtworks as a tool for anti-CAncer Drug Development we used phenotypic screening and genetic networks to identify the DNA repair protein MTH1 as a critical component for cancer cell survival and we developed selective sub nM inhibitors to MTH1, which specifically kill cancer cells and tumours, whilst being less toxic to primary cells. Our approach provides a novel concept for treating cancer. Here, we want to explore the commercial potential of the MTH1 inhibitors identified in the ERC grant."